Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

OBJECTIVE In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control in type 2 diabetes uncontrolled with GLP-1 RAs over 26 weeks versus continuing prior RA. A prespecified, 26-week, single-arm extension aimed determine durability iGlarLixi efficacy safety 52 weeks. RESEARCH DESIGN AND METHODS Participants by (glycated hemoglobin [HbA1c] 7–9% [53–75 mmol/mol]) were initially randomized switch or continue Those who completed 26-week primary end point period could open-label treatment assess safety. RESULTS Glycemic achieved at week (mean HbA1c 6.7% [50 was maintained mmol/mol]; mean ± SD change from baseline 52: −1.0 0.9% [11 10 mmol/mol]). Proportions participants reaching <7% (53 mmol/mol) similar (62%) (64%), as those this target without documented symptomatic (<3.0 mmol/L) hypoglycemia (57% 58%). Safety 52, low rates gastrointestinal events. CONCLUSIONS The trial.